NEW YORK (GenomeWeb News) – Life Technologies today announced it has acquired cancer bioinformatics firm Compendia for an undisclosed amount.

Based in Ann Arbor, Mich., Compendia develops products used by drug manufacturers for identifying novel gene targets in drug discovery and development, and according to Life Tech, its expertise in oncology and proprietary assets "enhance Life's diagnostic development capabilities across multiple platforms, including next-generation sequencing, qPCR, and proteome analysis."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.

May
28
Sponsored by
PerkinElmer

This online seminar will demonstrate how RNA-seq analysis in a model organism can provide insights into human disease. 

Jun
23
Sponsored by
PerkinElmer

This webinar will demonstrate how automated liquid handling workstations can reduce bottlenecks in library preparation for next-generation sequencing, enabling scientific advances in genomics research that were not possible five years ago.